| 
September 9, 2013
Guideline Summaries Royal Australian College of General Practitioners - Communicable diseases. In: Guidelines for preventive activities in general practice, 8th edition.
- Early detection of cancers. In: Guidelines for preventive activities in general practice, 8th edition.
- Genetic counselling and testing. In: Guidelines for preventive activities in general practice, 8th edition.
- Glaucoma. In: Guidelines for preventive activities in general practice, 8th edition.
- Oral hygiene. In: Guidelines for preventive activities in general practice, 8th edition.
- Osteoporosis. In: Guidelines for preventive activities in general practice, 8th edition.
- Prevention of chronic disease. In: Guidelines for preventive activities in general practice, 8th edition.
- Prevention of vascular and metabolic disease. In: Guidelines for preventive activities in general practice, 8th edition.
- Preventive activities in children and young people. In: Guidelines for preventive activities in general practice, 8th edition.
- Preventive activities in middle age. In: Guidelines for preventive activities in general practice, 8th edition.
- Preventive activities in older age. In: Guidelines for preventive activities in general practice, 8th edition.
- Preventive activities prior to pregnancy. In: Guidelines for preventive activities in general practice, 8th edition.
- Psychosocial. In: Guidelines for preventive activities in general practice, 8th edition.
- Screening tests of unproven benefit. In: Guidelines for preventive activities in general practice, 8th edition.
- Urinary incontinence. In: Guidelines for preventive activities in general practice, 8th edition.
| Announcements NGC Spotlight New clinician and consumer guides added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program. Revised Inclusion Criteria NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments. Health Awareness Topics - September 2013 Conference News - The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.
This month's topic, Clinical Practice Guidelines Adaptation will take place on Thursday September 12, 2013 at 12:00-1:30 p.m. (Pacific) 3:00-4:30 p.m. (Eastern). Information on how to join the webinar is available on the G-I-N Web site. U.S. Food and Drug Administration (FDA) Advisory - August 29, 2013: Gilenya (fingolimod): FDA is alerting the public that a patient in Europe diagnosed with possible multiple sclerosis (MS) has developed a rare and serious brain infection after taking the drug Gilenya (fingolimod). Patients should not stop taking Gilenya without first discussing any questions or concerns with their health care professionals. FDA is providing this alert while continuing to investigate the PML case, and is working with Gilenya's manufacturer, Novartis, to obtain and review all available information about this occurrence. FDA will communicate its final conclusions and recommendations after the evaluation is complete.
NGC's Sister Resources
| This email was sent to buzzhairs@gmail.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364 | |
No comments:
Post a Comment